Page 76 - Portuguese Journal - SPORL - Vol 61. Nº1

Figure 2
Flow chart of the PRISMA studies - Preferred Reporting Items for Systematic Reviews and Meta-
Analysis

difference of -6.57 (95% CI: -12.20, 0.94; P=0.02) Deaths during treatment were reported in
points in the SNOT-22 in the NCT03450083 some studies, but no death was related to the
and OSTRO studies, compared to the use of treatment.
placebo. With regard to the extension of the
disease, the use of benralizumab led to a Cost-benefit analysis of the biological
mean difference of -0.54 (95% CI: -0.72, -0.35; medications
P<0.00001) points in the NPS and -1.37 (95% CI: Rudmik et al. conducted a study in which FESS
-3.10, -0.37; P=0.12) points in the Lund-Mackay followed by postoperative medical treatment
Score in the NCT03450083 and OSTRO studies, was compared to continued medical
compared to the use of placebo, although (“conventional”) treatment for CRSwNP and
the result of the Lund-Mackay Score was not concluded that FESS was a more cost-effective
statistically significant. treatment strategy than continued medical
therapy alone, with FESS having a total cost
Adverse effects of $48,838,38 coupled to the production of
In most studies, the percentage of adverse a total of 20.50 quality adjusted life years
effects was similar between the treatment (QALYs) and medical treatment alone having
and placebo groups. No study reported severe a total cost of $28,948,98 associated with the
adverse effects associated with the treatment. production of 17.13 QALYs . The additional
32
The most common adverse effects were cost of FESS relative to continued medical
nasopharyngitis, headache, and injection site treatment alone was $5,901,90 per QALY, an
reaction. amount that is considered acceptable within

76 Portuguese Journal of Otorhinolaryngology - Head and Neck Surgery